{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:38:11Z","timestamp":1793147891681,"version":"4.5.0"},"reference-count":19,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n In the US, adjuvanted or higher-dose influenza vaccines are preferentially recommended for annual use among adults aged 65 years or older. Adjuvanted and high-dose influenza vaccines have not been compared in a pragmatic randomized study.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess the relative vaccine effectiveness (rVE) of adjuvanted vs high-dose inactivated influenza vaccine against polymerase chain reaction (PCR)\u2013confirmed influenza in older adults at Kaiser Permanente Northern California (KPNC).<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n In this cluster randomized crossover study, during the 2023 to 2024 influenza season, 65 KPNC facilities were cluster randomized such that approximately half of facilities administered adjuvanted and half high-dose influenza vaccine on the first week of the vaccination season (and thereafter every facility crossed over and alternated formulations weekly). Using Cox proportional hazards regression on a calendar time scale, the rVE of adjuvanted vs high-dose vaccine was estimated for each outcome as 1 minus the hazard ratio, adjusted for age, sex, race and ethnicity, comorbidities, and health care utilization. Study participants included all adults 65 years or older who were vaccinated with adjuvanted or high-dose inactivated influenza vaccine during routine care at a KPNC facility between August 17, 2023, and April 16, 2024.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Adjuvanted or high-dose inactivated influenza vaccine receipt during the 2023 to 2024 influenza season. Individuals were considered vaccinated 14 days after immunization.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was PCR-confirmed influenza in any clinical setting. Secondary outcomes were PCR-confirmed influenza with hospitalization or emergency department visits and hospitalization for community-acquired pneumonia. Outcomes were assessed starting October 1, 2023, or 14 days after vaccination, whichever came later.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n This study included 429\u202f595 individuals from the 2023 to 2024 influenza season (mean [SD] age, 75 [7] years; 236\u202f857 [55.1%] female; 86 287 [20.1%] Asian, 22\u202f910 [5.3%] Black, 53\u202f820 [12.5%] Hispanic, 1123 [0.3%] American Indian or Alaska Native, 2562 [0.6%] Pacific Islander, 252 709 [58.8%] White, 1638 [0.4%] multiracial, and 8546 [2.0%] unknown race), of whom 212\u202f875 (49.6%) received adjuvanted and 216\u202f720 (50.4%) received high-dose influenza vaccine. There were 836 cases of PCR-confirmed influenza (3.9 per 1000 persons) identified after adjuvanted and 867 cases (4.0 per 1000 persons) after high-dose vaccine. The rVE of adjuvanted compared with high-dose influenza vaccine was 1.5% (95% CI, \u22128.4% to 10.5%) against influenza, 9.1% (95% CI, \u22124.0% to 20.4%) against influenza with hospitalization or emergency department visits, and 1.0% (95% CI, \u221211.4% to 12.0%) against hospitalizations for community-acquired pneumonia.<\/jats:p>\n <\/jats:sec>\n \n Conclusion and Relevance<\/jats:title>\n In the first season of a large, ongoing study in adults 65 years or older, adjuvanted and high-dose influenza vaccines did not differ in effectiveness against laboratory-confirmed influenza during the 2023 to 2024 influenza season. Consistent with Advisory Committee on Immunization Practices recommendations, these results support the equivalency of adjuvanted and high-dose influenza vaccines for adults 65 years or older.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT06029933<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.10120","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:00:21Z","timestamp":1777906821000},"page":"e2610120","source":"Crossref","is-referenced-by-count":8,"title":["Adjuvanted vs High-Dose Influenza Vaccines in Older US Adults"],"prefix":"10.1001","volume":"9","author":[{"given":"Amber","family":"Hsiao","sequence":"first","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Leong","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Fireman","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hansen","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ousseny","family":"Zerbo","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen B.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren D.","family":"Liao","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mendel D. M.","family":"Haag","sequence":"additional","affiliation":[{"name":"CSL Seqirus, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"McGovern","sequence":"additional","affiliation":[{"name":"CSL Seqirus, Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[{"name":"CSL Seqirus, Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet","family":"Dang","sequence":"additional","affiliation":[{"name":"CSL Seqirus, Summit, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola P.","family":"Klein","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"issue":"1","key":"zoi260315r3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7101a1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022-23 influenza season.","volume":"71","author":"Grohskopf","year":"2022","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"zoi260315r4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7305a1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices - United States, 2024-25 influenza season.","volume":"73","author":"Grohskopf","year":"2024","journal-title":"MMWR Recomm Rep"},{"issue":"7","key":"zoi260315r5","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1056\/NEJMoa1315727","article-title":"Efficacy of high-dose versus standard-dose influenza vaccine in older adults.","volume":"371","author":"DiazGranados","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi260315r6","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1093\/cid\/ciae375","article-title":"Comparative effectiveness of licensed influenza vaccines in preventing influenza-related medical encounters and hospitalizations in the 2022-2023 influenza season among adults =65 years of age.","volume":"79","author":"Ku","year":"2024","journal-title":"Clin Infect Dis"},{"key":"zoi260315r7","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.ijid.2022.07.048","article-title":"Comparative effectiveness of adjuvanted versus high-dose seasonal influenza vaccines for older adults: a systematic review and meta-analysis.","volume":"122","author":"Domnich","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"8","key":"zoi260315r8","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae459","article-title":"Relative effectiveness of the MF59-adjuvanted influenza vaccine versus high-dose influenza vaccine in older adults with influenza risk factors during the 2019-2020 us influenza season.","volume":"11","author":"Imran","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"zoi260315r10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-080472","article-title":"Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration.","volume":"388","author":"McKenzie","year":"2025","journal-title":"BMJ"},{"issue":"24","key":"zoi260315r11","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1056\/NEJMoa2302099","article-title":"Recombinant or standard-dose influenza vaccine in adults under 65 years of age.","volume":"389","author":"Hsiao","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi260315r12","doi-asserted-by":"crossref","first-page":"597","DOI":"10.22237\/jmasm\/1257035100","article-title":"New effect size rules of thumb.","volume":"8","author":"Sawilowsky","year":"2009","journal-title":"J Mod Appl Stat Methods"},{"key":"zoi260315r13","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2025.103288","article-title":"Trends in influenza vaccine disparities in the U.S. following the introduction of COVID-19: insights from the national health interview survey.","volume":"60","author":"Lind","year":"2025","journal-title":"Prev Med Rep"},{"issue":"43","key":"zoi260315r14","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.15585\/mmwr.mm7143e1","article-title":"Vital signs: influenza hospitalizations and vaccination coverage by race and ethnicity-United States, 2009-10 Through 2021-22 influenza seasons.","volume":"71","author":"Black","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"408","key":"zoi260315r15","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1080\/01621459.1989.10478874","article-title":"The robust inference for the Cox proportional hazards model.","volume":"84","author":"Lin","year":"1989","journal-title":"J Am Stat Assoc"},{"key":"zoi260315r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2024.107160","article-title":"Relative vaccine effectiveness of MF59-adjuvanted vs high-dose trivalent inactivated influenza vaccines for prevention of test-confirmed influenza hospitalizations during the 2017-2020 influenza seasons.","volume":"146","author":"McGovern","year":"2024","journal-title":"Int J Infect Dis"},{"issue":"8","key":"zoi260315r17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.15585\/mmwr.mm7308a4","article-title":"Interim influenza vaccine effectiveness against laboratory-confirmed influenza\u2014California, October 2023-January 2024.","volume":"73","author":"Zhu","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"zoi260315r19","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1093\/cid\/ciae597","article-title":"Influenza vaccine effectiveness against hospitalizations and emergency department or urgent care encounters for children, adolescents, and adults during the 2023\u20132024 season, United States.","volume":"81","author":"Tenforde","year":"2024","journal-title":"Clin Infect Dis"},{"key":"zoi260315r1","unstructured":"Centers for Disease Control and Prevention. About Estimated Flu Burden. Accessed March 19, 2026. https:\/\/www.cdc.gov\/flu-burden\/php\/about\/index.html"},{"key":"zoi260315r2","unstructured":"Centers for Disease Control and Prevention. Flu and People 65 Years and Older. Accessed March 19, 2026. https:\/\/www.cdc.gov\/flu\/highrisk\/65over.htm"},{"key":"zoi260315r9","unstructured":"Gordon? N. Similarity of adult Kaiser Permanente members to the adult population in Kaiser Permanente\u2019s Northern California service area: comparisons based on the 2017\/2018 cycle of the California Health Interview Survey. 2020. Accessed March 19, 2026. https:\/\/divisionofresearch.kaiserpermanente.org\/projects\/memberhealthsurvey\/SiteCollectionDocuments\/compare_kp_ncal_chis2017-18.pdf"},{"key":"zoi260315r18","unstructured":"Centers for Disease Control and Prevention. Influenza activity in the United States during the 2023\u20132024 season and composition of the 2024\u20132025 influenza vaccine. 2024. Accessed March 19, 2026. https:\/\/www.cdc.gov\/flu\/whats-new\/flu-summary-2023-2024.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2848563\/hsiao_2026_oi_260315_1777310768.75815.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:00:25Z","timestamp":1777906825000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2848563"}},"subtitle":["A Cluster Randomized Crossover Study"],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.10120","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]}}}